Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia-Reference-Cited by-同舟云学术

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia

Published:2014-08-28 Issue:9 Volume:124 Page:1513-1521
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Malcovati Luca¹²,Papaemmanuil Elli³,Ambaglio Ilaria²,Elena Chiara²,Gallì Anna²,Della Porta Matteo G.²⁴,Travaglino Erica²,Pietra Daniela²,Pascutto Cristiana²,Ubezio Marta¹²,Bono Elisa¹²,Da Vià Matteo C.¹²,Brisci Angela⁵,Bruno Francesca⁵,Cremonesi Laura⁵,Ferrari Maurizio⁵,Boveri Emanuela⁶,Invernizzi Rosangela⁴,Campbell Peter J.³,Cazzola Mario¹²

Affiliation:

1. Department of Molecular Medicine, University of Pavia, Pavia, Italy;

2. Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;

3. Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom;

4. Department of Internal Medicine, University of Pavia, Pavia, Italy;

5. Genomic Unit for the Diagnosis of Human Pathologies, San Raffaele Scientific Institute, Milan, Italy; and

6. Department of Human Pathology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy

Abstract

Key Points Different driver mutations have distinct effects on phenotype of myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Accounting for driver mutations may allow a classification of these disorders that is considerably relevant for clinical decision-making.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/9/1513/1383279/1513.pdf

Reference36 articles.

1. Introduction and overview of the classification of the myeloid neoplasms.;Vardiman

2. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.;Malcovati;Blood,2013

3. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.;Senent;Haematologica,2013

4. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.;Naqvi;Blood,2011

5. The genetic basis of myelodysplasia and its clinical relevance.;Cazzola;Blood,2013

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation;Hematology;2024-08-20

2. Characterisation and prognostic impact of ZRSR2 mutations in myeloid neoplasms;2024-07-15

3. Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia;Leukemia & Lymphoma;2024-07-14

4. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms;Leukemia Research;2024-01

5. How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome;Hematology;2023-12-08